{"id":"placebo-to-match-obv-ptv-r-and-dsv","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos are inactive substances used in clinical trials as control comparators to isolate the true therapeutic effect of an active drug. This particular placebo was manufactured to be indistinguishable from OBV/PTV/r and DSV (a hepatitis C antiviral regimen) in terms of physical properties and dosing schedule, ensuring blinding of trial participants and reducing bias in efficacy and safety assessments.","oneSentence":"This is an inert placebo formulation designed to match the appearance, taste, and administration characteristics of the active combination of ombitasvir/paritaprevir/ritonavir and dasabuvir.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:36:14.678Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in clinical trials of ombitasvir/paritaprevir/ritonavir and dasabuvir for hepatitis C"}]},"trialDetails":[{"nctId":"NCT03003338","phase":"PHASE4","title":"MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2017-10-24","conditions":"Hepatitis C, Chronic","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo to match OBV/PTV/r and DSV","genericName":"Placebo to match OBV/PTV/r and DSV","companyName":"Hannover Medical School","companyId":"hannover-medical-school","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is an inert placebo formulation designed to match the appearance, taste, and administration characteristics of the active combination of ombitasvir/paritaprevir/ritonavir and dasabuvir. Used for Control arm in clinical trials of ombitasvir/paritaprevir/ritonavir and dasabuvir for hepatitis C.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}